Context Therapeutics CEO awarded 815K stock options

Context Therapeutics Inc. reported that Chief Executive Officer Martin A. Lehr received a grant of stock options for 815,000 shares at an exercise price of $0.00 per share.

Accepted by SEC EDGAR 02/23/2026 - 04:13 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Context Therapeutics Inc. reported that Chief Executive Officer Martin A. Lehr received a grant of stock options for 815,000 shares at an exercise price of $0.00 per share. The option vests over four years, with 25% vesting on February 19, 2027 and the rest in equal monthly installments over the following three years, contingent on continued service.

Insider Trade Summary

Grant/Award: 815,000 shares

Grant/Award 1 txn

Insider Lehr Martin A.

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	815,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 815,000 contracts (Direct)

Holdings Before and After: Stock Option (right to buy), 0 to 815,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 19, 2027, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Context Therapeutics (CNTX) disclose?

Context Therapeutics reported a stock option grant to its CEO, Martin A. Lehr, covering 815,000 shares. The options were awarded at an exercise price of $0.00 per share as part of his equity compensation, subject to a multi-year vesting schedule tied to continued service.

Who received the stock options in the latest CNTX Form 4?

Chief Executive Officer Martin A. Lehr received the stock options reported in the filing. He was granted options for 815,000 shares, exercisable at $0.00 per share, aligning his compensation with the company’s long-term performance through a four-year vesting period based on continued service.

How many stock options were granted to the CNTX CEO?

Martin A. Lehr was granted stock options for 815,000 shares of Context Therapeutics common stock. These options vest over four years, beginning with a 25% cliff vesting on February 19, 2027, followed by equal monthly vesting installments over the remaining three years of the term.

What is the exercise price of Martin Lehr’s CNTX stock options?

The stock options granted to Martin A. Lehr carry an exercise price of $0.00 per share. This means he can acquire shares without additional cash cost once options vest, subject to the four-year vesting schedule and his continued service with Context Therapeutics.

What is the vesting schedule for the CNTX CEO’s stock options?

The option vests over four years. Twenty-five percent of the grant becomes exercisable on February 19, 2027, with the remaining 75% vesting in equal monthly installments over the next three years, conditioned on Martin A. Lehr’s continued service with Context Therapeutics.

Does the CNTX Form 4 indicate a purchase or a grant?

The Form 4 reflects a grant of stock options, not an open-market purchase. The transaction is coded as an acquisition related to a grant or award, providing 815,000 options at a $0.00 exercise price, subject to a structured four-year vesting schedule tied to ongoing employment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lehr Martin A.

(Last) (First) (Middle)

2001 MARKET STREET

SUITE 3915, UNIT #15

(Street)

PHILADELPHIA PA 19103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Context Therapeutics Inc. [ CNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.32	02/19/2026		A		815,000		(1)	02/18/2036	Common Stock	815,000	$0	815,000	D

Explanation of Responses:

1. The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 19, 2027, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

Remarks:

	/s/ Alex Levit, Attorney-in-Fact	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.